Company intelligence / Profile preview

Myobid

Ownership: Private
Development stage: Other

Overview

MyoBid is an early-stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of cardiovascular diseases, specifically heart failure and cardiomyopathies. The company's research centers on modulating cardiac myosin to improve heart muscle function and efficiency. By targeting the fundamental motor proteins of the heart, MyoBid aims to provide disease-modifying treatments for patients with limited therapeutic options. The company is currently in the pre-clinical stage, advancing its lead candidates through optimization and safety studies.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Myobid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myobid.

Explore the full profile